Clinical Sciences

A macrophage cell therapy that is being developed by spinout Resolution Therapeutics shows promise as the first treatment for advanced liver disease, following results from a clinical trial.

Two University of Edinburgh spinouts were recognised last night at the Scottish Knowledge Exchange Awards 2026.

A test that rapidly detects signs of inflammatory bowel disease (IBD) in stool samples could improve future diagnosis and monitoring of the condition, a study suggests.

Biopharmaceutical spinout Resolution Therapeutics has announced the first patient has been dosed and safety cleared in the Phase I/II EMERALD study of its novel therapy for end-stage liver disease.

Scotland’s first total-body scanner - set to accelerate drug development and diagnosis for patients - is now in operation at the Royal Infirmary of Edinburgh.

Global biopharmaceutical company Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) and viral vector manufacturing company OXB have announced the start of a Phase I/II trial of a novel gene therapy that could improve outcomes for people with cystic fibrosis.

Data scientists and clinical researchers are working with high street opticians for the first time to develop a digital tool that can predict a person’s risk of dementia from a routine eye test.

A new £50m Centre aims to develop the first therapies to stimulate heart repair and regeneration in patients with heart disease.